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Coculture With Mesenchymal Stem Cells Results in Improved Viability
and Function of Human Hepatocytes
Emer Fitzpatrick,* Yue Wu,† Paramjeet Dhadda,† Robin D. Hughes,† Ragai R. Mitry,† Hong Qin,†
Sharon C. Lehec,† Nigel D. Heaton,† and Anil Dhawan*
*Paediatric Liver, GI and Nutrition Centre, King’s College London School of Medicine at King’s College Hospital,
Denmark Hill, London, UK
†Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, Denmark Hill, London, UK
Hepatocyte transplantation is becoming an accepted therapy for acute liver failure, either as a bridge to liver
regeneration or to organ transplantation. Hepatocytes provide liver function in place of the failing organ. The
maintenance of sufficient viability and function of the transplanted hepatocytes is a concern. There is a lot of
recent interest in mesenchymal stem cells (MSCs) for the provision of structural and trophic support to
hepatocytes, but few studies currently use primary human hepatocytes. The aim of this study was to investigate
if coculture of human MSCs with cryopreserved human hepatocytes may improve their function and viability,
thus with potential for cellular therapy of liver disease. MSCs were isolated from human umbilical cord or adi-
pose tissue. Hepatocytes were isolated from donor organs unsuitable for transplantation. MSCs and hepatocytes
were cocultured in both direct and indirect contact. Conditioned medium (CM) from cocultured MSCs and
hepatocytes was also used on hepatocytes. Viability and liver-specific function were compared between test and
controls. Human hepatocytes that were cocultured directly with MSCs demonstrated improved production of
albumin from day 5 to day 25 of culture. This effect was most prominent at day 15. Likewise, urea production
was improved in coculture from day 5 to 25. Indirect coculture demonstrated improved albumin production by
day 4 (1,107 ng/ml) versus hepatocyte monoculture (940 ng/ml). Hepatocytes in CM demonstrated a nonsignifi-
cant improvement in function. The viability of cocultured hepatocytes was superior to that of monocultured cells
with up to a 16% improvement. Thus, coculture of human hepatocytes with MSCs demonstrates both improved
function and viability. The effect is seen mainly with direct coculture but can also be seen in indirect culture and
with CM. Such coculture conditions may convey major advantages in hepatocyte survival and function for
cell transplantation.
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INTRODUCTION
Hepatocyte transplantation is making its transition
from bench to bedside for both liver-based metabolic
disorders and acute liver failure. Over 80 patients have
now been transplanted worldwide, and the safety of the
procedure together with medium-term success has been
established (10). A major limiting factor in the field is the
availability of good-quality cells, as hepatocytes are gen-
erally derived from grafts that are deemed unsuitable for
transplantation. There is also a need to develop tech-
niques that will improve the engraftment, survival, and
function of transplanted hepatocytes (8). A major advan-
tage of hepatocyte transplantation is the ability to cryopre-
serve cells once they are isolated from donor livers. The
cells can then be stored and thawed for use whenever
required, which is important in the treatment of acute
liver failure. Cryopreservation, however, can have delete-
rious effects on cell viability and on the attachment and
thus possibly the engraftment of cells (30).
Recent advances have directed attention toward the
clinical potential of using stem cells in cell transplanta-
tion. In particular, mesenchymal stem cells (MSCs) have
great promise in this respect. MSCs are multipotent,
adherently growing cells, which provide support for
hematopoietic cells within the bone marrow (9). They are
a readily available source of stem cells that can also be
isolated from umbilical cord blood and matrix, placental
tissue, adipose tissue, and other sources (2,7). MSCs play
a major role in tissue repair, both through localized
immune-suppressive effects and through the release of
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soluble trophic factors to affect neighboring cells, proper-
ties that make them excellent candidates for improving
the survival of transplanted cells (22–24). MSCs also have
antiapoptotic, proregenerative effects in the setting of myo-
cardial infarction, kidney failure, and stroke (12,18).
MSCs have been shown to differentiate into hepa-
tocytes in appropriate conditions in vitro and in vivo (1,5).
In addition, they can modulate liver injury and promote
native liver regeneration (3,23) with improved survival in
animal models of liver disease and in pilot clinical studies
of liver failure (13,16,17,27). It is not known whether this
therapeutic effect is due to the potential of MSCs to dif-
ferentiate into hepatocytes in the appropriate microenvi-
ronment or to their stimulatory/trophic effects. A major
limitation of previous coculture studies has been the use
of nonhuman (usually rodent) cells that do not necessarily
behave in the same way as human cells. Understanding
the behavior of human cells in this context is particularly
important prior to translation to the clinical setting. The
hypothesis of this study is that MSCs will promote human
hepatocyte viability and function. This study focuses on
the in vitro coculture of different sources of MSCs (adi-
pose derived and umbilical cord matrix derived) with cryo-
preserved human hepatocytes. Both umbilical cord and
adipose tissue are readily available sources of MSCs and
were considered practical for potential translation to clini-
cal practice.
MATERIALS AND METHODS
Isolation and Cryopreservation of Human Hepatocytes
Human liver tissue was obtained from donor tissue
that was rejected or unused for orthotopic liver transplan-
tation or from liver resections at King’s College Hospital
(London, UK). Consent was obtained to use all the tissue
for research in accordance with the Research Ethics Com-
mittee of King’s College Hospital. Tissue was anonymized
at the source. Isolation of human hepatocytes was carried
out using a modified collagenase perfusion technique (20).
The isolated hepatocytes were cryopreserved in Univer-
sity of Wisconsin solution (Bristol-Myers Squibb Pharma
Ltd., Uxbridge, Middlesex, UK)/10% dimethyl sulfoxide
(DMSO; Sigma-Aldrich, Poole, Dorset, UK) (v/v)/5% glu-
cose (Sigma-Aldrich) using a controlled rate freezer and
stored at −140°C for later use (31).
Isolation and Expansion of Human Mesenchymal Stem
Cells From Umbilical Cord Matrix (UC-MSCs)
MSCs were isolated from human umbilical cord matrix
(4). The umbilical cord was transferred in 0.9% NaCl ster-
ile solution on ice and processed immediately. The cords
were incised along their length to expose underlying
Wharton’s jelly, and the umbilical vein and the arteries
were pulled away. The remaining mesenchymal tissue
was scraped off with a sterile scalpel and centrifuged at
250 × g for 5 min at room temperature. The pellet was
resuspended in Hank’s balanced salt solution (HBSS)
(Lonza, Castleford, UK) containing 1 mg/ml collage-
nase type I (Sigma-Aldrich) and 100 U/ml penicillin/
100 µg/ml streptomycin (Invitrogen, Paisley, UK). The
tissue was transferred to a T75 flask (Thermo-Scientific
Nunc, Hemel Hempstead, UK) with a ventilated cap
and digested at 37°C in a humidified atmosphere con-
taining 5% CO2 overnight. The homogenate was diluted
in phosphate-buffered saline (PBS), triturated with a glass
Pasteur pipette, and centrifuged at 400 × g for 10 min. The
cell pellet was resuspended in Dulbecco’s modified Eagle
medium (DMEM; Invitrogen) with 10% (v/v) fetal bovine
serum (FBS; Invitrogen) and 100 U/ml penicillin/100 µg/ml
streptomycin. Trypan blue exclusion assay (Invitrogen) was
used to count the viable cells, and the cells were plated in a
T75 flask and incubated at 37°C in a humidified atmo-
sphere containing 5% CO2. The medium was changed
after 24 h to remove the nonadherent cells. When cultures
reached confluence, the cells were trypsinized using trypsin
(Gibco, Paisley, UK) and subcultured in fresh flasks.
Isolation of Adipose-Derived MSCs (AD-MSCs)
AD-MSCs were also used for experiments and were
purchased from Invitrogen. These cells had been isolated
using mechanical and enzymatic digestion following
harvesting from lipo-adipose suction. The AD-MSCs had
been purified following labeling with antibodies [cluster
of differentiation 29 (CD29), CD44, CD73, CD90, CD105,
CD166] and flow cytometry sorting. The cells were cryo-
preserved and, following thawing, were cultured as above.
The ninth through the 12th passages were used for fur-
ther experiments.
Immunophenotyping of UC-MSCs
Undifferentiated UC-MSCs were trypsinized and
suspended in PBS/1% FBS and then incubated with the
following fluorescein isothiocynate (FITC)-, phycoerythrin
(PE)-, or allophycocyanine (APC)-conjugated antibodies:
CD13 (1 mg/test), CD105 (0.25 mg/test), CD90 (1 mg/test),
CD44 (0.5 mg/test), CD117 (0.25 mg/test), CD31 (0.125 mg/
test) (all eBioscience, Hatfield, UK), CD73 (0.5 mg/test),
and human leukocyte antigen (HLA)-DR (20 ml/test) (both
BD Pharmingen, Oxford, UK) for 30 min at 4°C. The
cells were then washed and resuspended in 0.5 ml PBS.
Cells were analyzed on a FACSCanto II flow cytometer
(BD Biosciences), and at least 10,000 events were acquired
for each sample.
Adipogenic and Osteogenic Differentiation of UC-MSCs
Adipogenic differentiation was induced by cultivation of
confluent cultures in DMEM containing 20% (v/v) FBS,
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2.5 µg/ml insulin, 100 µmol/L indomethacin, 5 µmol/L
rosiglitazone, and 10 nmol/L dexamethasone (all from
Sigma-Aldrich) for 4 weeks with medium changes twice
a week. Differentiated cells were analyzed by staining
lipid vesicles with Oil Red O (Sigma-Aldrich).
For osteogenic differentiation, the cells were cultured
in DMEM containing 10% (v/v) FBS, 10 mmol/L b-
glycerophosphate (Sigma-Aldrich), 5 µg/ml ascorbic acid
(Sigma-Aldrich), and 10 nmol/L dexamethasone for 4 weeks
with medium changes twice a week. Calcium deposition
was evaluated by Alizarin Red S staining (Sigma-Aldrich).
Coculture of Human Hepatocytes
With MSCs
Cryopreserved human hepatocytes were used for
experiments. Batches that did not reach 70% viability
after Percoll (GE Healthcare, Little Chalfont, UK) follow-
ing thawing were not used. Cells were seeded into each
collagen IV-coated culture vessel (collagen IV from
Sigma-Aldrich) at a fixed density of 1.5 × 105/cm2 live
cells (to standardize). UC-MSCs or AD-MSCs were
added once hepatocytes (HCs) were attached using HCs
to MSCs ratios of 3:1, 6:1, and 10:1. Experiments com-
pared coculture to HC monoculture with equal numbers
of HCs. The cells were cocultured in William’s medium
E (Sigma-Aldrich) supplemented with 10% FBS, 10 nM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES;
Cambrex, Invitrogen), 2 mM glutamine (Invitrogen), 0.5 µg/
ml (10−7 M) insulin (Sigma-Aldrich), and 10−7 M dexameth-
asone. This is standard HC culture medium. The medium
was changed the following day and 24 h later. The super-
natant was collected and stored at −80°C for later analysis.
The media were then collected every other day afterward
with the media changed 24 h before. Indirect coculture was
undertaken using a porous Transwell membrane, pore size
0.4 mm (BD Biosciences). HCs were first seeded at a den-
sity of 1.5 × 105/cm2 on the collagen-coated plate. Once
attached, the MSCs were seeded onto the Transwell mem-
brane inserts at a density of 1.5 × 104. Again, the medium
was changed 24 h later and then collected at days 1, 2,
and 4 with medium change 24 h prior to each time point.
Hepatocytes were also cultured using conditioned
medium, which was collected from cocultures of HCs/
UC-MSCs. This was to elicit the possible effects on HCs
of paracrine factors secreted by UC-MSCs when in con-
tact with HCs. The HCs and UC-MSCs were cultured in
standard culture medium for 24 h before the conditioned
medium was collected. The conditioned medium was
then diluted with the same amount of fresh standard cul-
ture medium to achieve HCs/UC-MSCs equivalent ratios
of 3:1 and applied to the HC monoculture. Human HCs
cultured in standard medium only, medium conditioned
from UC-MSC culture alone, and standard HC culture
medium only and HCs in direct coculture with UC-MSCs
were used as controls.
Albumin Secretion ELISA
Albumin concentration in the medium was measured
using human albumin enzyme-linked immunosorbent
assay (ELISA) quantification kit (Bethyl Laboratories,
Montgomery, TX, USA) according to the manufacturer’s
instructions.
Urea Production
Urea concentration in the medium was measured using
QuantiChrome Urea Assay Kit (BioAssay Systems, Cam-
bridge, UK) according to the manufacturer’s instructions.
Identification of Liver-Specific Genes in MSCs Following
Coculture Using Reverse Transcription Polymerase
Chain Reaction (RT-PCR)
Total RNA was extracted from both HCs and MSCs
grown in both indirect coculture and in monoculture
(controls) using TRIzol® and reverse transcribed to cDNA
using Omniscript® Reverse Transcriptase kit (Qiagen,
Crawley, West Sussex, UK) according to the manufacturers’
protocols. PCR amplification was undertaken using primers
(Eurofins MWG Operon, Ebersburg, Germany) for human
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (fw:
5¢-cggagtcaacggatttggtcgtat-3¢, rv: 5¢-agccttctccatggtggt
gaagac-3¢), albumin (fw: 5¢-ccttggtgttgattgcctttgctc-3¢, rv:
5¢-catcacatcaacctctggtctcacc-3¢), and cytokeratin 18 (fw: 5¢-
ccatgcgccagtctgtggag-3¢, rv: 5¢-agcagattgaggagagcaccac-3¢).
PCR products were amplified using Thermo Scientific Px2
Thermal Cycler and then analyzed using 2% agarose gel
electrophoresis (Sigma-Aldrich).
Viability Studies
Viability of HCs was assessed using trypan blue,
Annexin-V/propidium iodide staining (Promega, Southampton,
UK) with flow cytometry, the M30 CytoDeath ELISA
assay (PEVIVA, distributed by Bioaxxess, Tewkesbury,
UK, which measures cleavage of cytokeratin 18) on the
cell lysate and supernatant as well as RT-PCR for caspase
3 expression. Real-time PCR was undertaken using RNA
isolated from HCs in indirect coculture as above, and fol-
lowing reverse transcription, relative quantification real-
time PCR was undertaken using a gene expression assay
(probe) for caspase 3, TaqMan® Universal Master Mix,
and ABI Prism7000 Sequence detection system (Applied
Biosystems, Warrington, UK).
Data Analysis
Values are expressed as means ± standard deviation (SD).
The statistical significance of differences between groups
was tested using one-way analysis of variance (ANOVA,
75IMPROVED FUNCTION OF HEPATOCYTES IN MSC COCULTURE
with Bonferroni correction) or Student’s t test. A level of
p £ 0.05 was considered to be statistically significant.
RESULTS
Isolation of Human MSCs From Human Umbilical
Cord Matrix
Spindle-shaped cells (Fig. 1A) expressed MSC-specific
markers CD13, CD73, CD105, CD44, and CD90, but not
CD31, CD117, or HLA-DR (Fig. 1B). In vitro differenti-
ation to adipogenic and osteogenic cells was also demon-
strated (data not shown). These results suggested that
the cells isolated were UC-MSCs fulfilling the criteria of
the Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy (9).
In Vitro Coculture of Human HCs
and Human AD-MSCs
There was increased albumin production in the cocul-
ture system from day 3 onward as shown in Figure 2.
This effect was seen across all ratios of HCs to AD-
MSCs. Albumin secretion of the HCs in monoculture
decreased from day 3, and by day 9 it was undetectable.
On the other hand, there was continuous production of
albumin in all cocultured cells. There was a gradual
increase of albumin production in cocultured cells that
were in 6:1 and 3:1 ratios. From these results, it seems
that AD-MSCs can help maintain HC function in vitro
via direct contact coculture of these two types of cells.
Long-Term In Vitro Coculture of
Human HCs With UC-MSCs
Human HCs cocultured with UC-MSCs also showed
improved albumin production (Fig. 3) as those cocultured
with AD-MSCs. At day 1, human HCs cultured under the
different conditions secreted similar amounts of albumin
followed by a fall over the first 5 days. However, after
day 5, albumin secretion from the HCs cocultured with
UC-MSCs continuously increased until day 15, while that
from the HCs in monoculture decreased. UC-MSCs
induced a significant increase in albumin secretion by
HCs into the culture medium, approximately 15-fold at
day 15 (2,190 ± 170 ng/24 h/well) at 3:1 ratio compared
to day 1 (140 ± 5 ng/24 h/well, p < 0.001). In both
cococulture systems, MSCs were also cultured alone as
a control. Neither AD-MSCs nor UC-MSCs secreted
albumin in monoculture.
Hepatocytes cocultured in different ratios with UC-
MSCs using different coculture ratios produced similar
amounts of urea, which was maintained at day 3 but fell
by day 5 (Fig. 4). However, after day 5, urea production
from the HCs cocultured with UC-MSCs continuously
increased until day 13, while that from the HCs in
Figure 1. Characterization of isolated MSCs from umbilical cord matrix. (A) Morphology of UC-MSCs using phase-contrast light
microscope 100× magnification. Cells are spindle-shaped and fibroblast-like. (B) Flow cytometric analysis of human UC-MSCs.
UC-MSCs were positive for cluster of differentiation 13 (CD13), CD73, CD105, CD90, and CD44 and negative for CD31, CD117,
and human leukocyte antigen (HLA)-DR.
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monoculture continued to decrease and was undetectable
from day 13. Even at day 25, urea production in the
cocultured HCs (3:1 ratio to UC-MSCs) was still higher
than day 1. UC-MSCs cultured alone did not pro-
duce urea.
Indirect Coculture of AD-MSCs and HCs
Indirect coculture was undertaken through a porous
Transwell membrane in order to determine if paracrine
effects may be responsible for the improved function of
HCs as seen in direct coculture. By day 4, albumin
Figure 2. Albumin secretion in cryopreserved HCs monocultured and cocultured with AD-MSCs at ratios of HCs to MSCs of 3:1
and 6:1. Monoculture or coculture was undertaken for 2 weeks and albumin expression measured using ELISA. Albumin produc-
tion was significantly increased in coculture from day 5 up to day 15 at both 3:1 and 6:1 ratios (n = 3; *p < 0.001 compared to
HC monoculture).
Figure 3. Albumin secretion from cryopreserved human HCs cocultured with UC-MSCs compared with HC monoculture. Condi-
tions were maintained over 25 days. There was a significant increase in albumin production from cocultured cells from day 5 until
day 25. This was seen at all ratios of HCs to MSCs but was best at 3:1 ratio (n = 3; *p < 0.001 compared to HC monoculture).
77IMPROVED FUNCTION OF HEPATOCYTES IN MSC COCULTURE
secretion by HCs in coculture was 1,107 ± 70 ng/ml/24 h
versus 941 ± 17 ng/ml/24 h in HCs cultured alone. How-
ever, this did not meet statistical significance.
The Effect of UC-MSC Conditioned Medium (CM) on
Human HC In Vitro Culture
Figure 5 shows albumin secretion from HCs cultured
using either CM from cocultures of HCs and UC-MSCs
in 3:1 or 6:1 ratios or HCs alone (control). Though there
was no significant effect in the first few days of culture,
by day 5 there was a significantly greater production of
albumin by HCs cultured in medium that was conditioned
by HCs and UC-MSCs in coculture. Overall, HCs cul-
tured in CM showed less effect on HC function demon-
strated by albumin secretion compared to that from the
direct contact coculture, but it was still considerately
higher than that from the cells cultured in regular HC
medium. HCs cultured in medium conditioned by UC-MSCs
alone did not show any increase in albumin production
versus standard culture medium.
Morphology and Viability of Cocultured Cells
The morphology of the HCs in monoculture and
cocultured with UC-MSCs in 6:1 ratio is shown in Figure 6.
At day 1, there was no visible difference in the
morphology of HCs cultured in these two conditions (Fig.
6A, B). The cells showed typical morphology of HCs
cultured in vitro. They were polygonal, some of which
had two nuclei. However, at day 7, monocultured HCs
(Fig. 6C) lost their morphological integrity, while the cells
cocultured with UC-MSCs (Fig. 6D) were still joined
together and growing well. By day 13, the majority of the
cells in monoculture (Fig. 6E) were dead while HCs
cocultured with UC-MSCs in 6:1 ratio were still healthy
and growing in a sheet-like fashion where HCs exhibited
stereotypical polygonal morphology with distinct nuclei
and nucleoli and well-demarcated cell–cell borders.
Trypan blue staining confirmed this finding with a via-
bility of 40.4 ± 7.6% in cocultured HCs versus 23.5 ± 3.5%
in monocultured cells.
RT-PCR was used to detect expression of caspase 3 in
HCs that were cocultured versus monocultured hepatocytes.
There was a demonstrable decrease in expression of the
marker in cocultured cells (data not shown). The M30
CytoDeath ELISA kit was also used to detect apoptosis
in cultured HCs as this marker will only measure HC
rather than MSC death. Measurement of cleavage of
cytokeratin 18 (CK18) showed that the CK18 fragment
level in HCs cocultured with UC-MSCs at 3:1 ratio
(0.0048 units) was much lower than that for HCs in
Figure 4. Urea production from cryopreserved human HCs cocultured with UC-MSCs at three different ratios (10:1, 6:1, and 3:1)
versus HC monoculture over 25 days in culture. Urea production was significantly improved in coculture from day 5 to day 25.
This was highest at day 13 but was maintained through to day 25. All ratios of HCs to MSCs demonstrated this effect, but the 3:1
ratio demonstrated the optimal effect (n = 3; *p < 0.001 or &p < 0.01 compared to HC monoculture).
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monoculture (0.3157 units) at day 15 and through 1 month
culture (Fig. 7).
Transdifferentiation of MSCs May Partly,
but Not Completely, Explain the Improved HC
Functionality in Coculture
AD-MSCs from indirect cocultures were harvested and
underwent PCR for albumin and CK18 expression. Though
albumin was demonstrably expressed following 72 h of
coculture, differentiation was only partial as demonstrated
by there being no expression of CK18 expression (data
not shown).
DISCUSSION
Coculture of human HCs and AD-MSCs or UC-MSCs
was demonstrated to help human HCs maintain their
function long term in vitro culture compared to HC
monoculture. This effect was best seen in direct coculture
systems but also seen using conditioned medium from
coculture. The latter suggests the possible contribution of
paracrine factors secreted by HC-stimulated MSCs. These
data also demonstrate that total cell death (and specifi-
cally HC apoptosis) was decreased in both direct and
indirect cocultures. It is likely that increased function is
due at least in part to improved survival.
Previous studies have demonstrated that bone marrow-
derived stem cells (BMSCs) have a protective effect on
rodent HCs in vitro and in vivo. Isoda et al. demonstrated
that BMSCs supported HC function when in coculture.
They hypothesized that interleukin 6 (IL-6) was responsible
for the improved production of urea, though not of
albumin (14). Coculture and cotransplantation of BMSCs
in Nagase analbuminemia rats and HCs demonstrated
improved function in vitro and in vivo (29). Liu and
Chang demonstrated coencapsulation and transplantation
of BMSCs, and HCs resulted in improved lowering of
bilirubin in Gunn rats (19). Recently, MSCs have become
a focus for attention in this context (6,24). Coculture of
rat MSCs with HCs in a liver-assist device (LAD) dem-
onstrated survival benefits over LAD with HCs alone in a
rat model of acute liver failure (32). Mohajerani et al.
transplanted human HCs detached from cocultures with
BMSCs into mice and found improved engraftment (21).
MSCs are known to provide structural support for cells in
the body and have antiapoptotic, immunomodulatory
effects. Gomez-Aristizabal et al. explored the effects of
bone marrow-derived mesenchymal stem cells (BM-MSCs)
and umbilical cord perivascular cells cocultured with rat
HCs and human lymphocytes and found a profunction effect
on the HCs and an anti-inflammatory effect when cocultured
with lymphocytes (11). These benefits are likely mediated
by a combination of both cell-to-cell contact and through
soluble factors (i.e., growth factors, cytokines, extracellu-
lar matrix glycoproteins) (3).
Improved production of albumin, possibly secondary
to transdifferentiation of MSCs into HC-like cells, was
Figure 5. Albumin secretion from HCs cultured in either HC culture medium (control) or CM from cocultures of HCs/MSCs,
which were cultured at a HC/MSC ratio of 6:1 and 3:1. Concentration of albumin in the CM that was added was measured sepa-
rately and subtracted from the result from the corresponding well. This demonstrates improved albumin production in HCs that
were cultured in medium from previous cocultures of HCs and MSCs (n = 3; *p < 0.001 or &p < 0.01 compared to HC conditioned
medium alone).
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seen in a pig model of fulminant liver failure with
intraportal transplantation of BM-MSCs (17). We have
demonstrated the expression of albumin at a gene, but not
at a protein level, in MSCs, which have been in indirect
coculture with HCs. It is more likely that injured HCs
induce the production of cytokines/growth factors by MSCs,
which, in turn, improves viability and function of HCs, for
example, IL-6 or hepatocyte growth factor (HGF) (15).
We show that culture of HCs in medium previously
conditioned by cocultured HCs and MSCs demonstrated
Figure 6. Morphology of the HCs in monoculture (A, C, E) and cocultured with UC-MSCs in 6:1 ratio (B, D, F) at day 1, 7, and
13, respectively, under the phase-contrast light microscope (200×). This demonstrates fewer surviving HCs over the period in
monoculture versus coculture.
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improved function, whereas HCs cultured in medium
conditioned by MSCs alone did not show an effect. This
may suggest that the presence of HCs is needed to stimu-
late MSCs to produce the relevant factors/cytokines. Cell-
to-cell contact may also have a role in provision of struc-
tural support for growing HCs; of note, HC function in
direct coculture was superior to that in indirect coculture.
This supportive role of MSCs is particularly promising
in the context of cell transplantation for acute liver failure
(ALF). Hepatocyte transplantation alone may provide a
bridge to either regeneration of the native liver or to
transplantation, allowing sufficient time for an organ to
become available (25,26,28). MSCs are a potential alter-
native to HC transplantation for ALF, as discussed.
Though they may hasten native liver recovery, MSCs will
not necessarily provide the missing liver function. Trans-
plantation of both MSCs and HCs in ALF may provide the
optimal combination of liver support with anti-inflammatory
effects (11,20).
In summary, direct coculture with UC- and AD-MSCs
appears to improve viability and function of HCs. This
effect was not seen with CM from MSCs alone, but there
was an effect seen with CM from cocultures of HCs and
MSCs. This could suggest that the presence of HCs is
necessary to stimulate the MSCs to secrete prosurvival
factors. The combination of transplanted HCs and MSCs
may have great promise in the cellular therapy of ALF,
in particular.
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